Press Releases Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
11.32 ^USD	-2.16%		-2.83%	+316.18%

May. 10	Skye Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Skye Bioscience, Inc.(NasdaqGM:SKYE) added to NASDAQ Transportation Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting	May. 13	AQ
Skye Bioscience Uplists to The Nasdaq Global Market	Apr. 10	AQ
SKYE BIOSCIENCE : AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS - Form 8-K	Apr. 03	PU
Skye Bioscience Announces $40 Million Private Placement Equity Financing	Mar. 11	NE
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors	Mar. 04	AQ
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension	Feb. 26	AQ
Skye Bioscience to Present at Oppenheimer Investor Conference	Feb. 07	NE
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing	Jan. 29	NE
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease	Jan. 09	NE
Skye Bioscience Responds to OTC Markets Promotional Policy	Dec. 11	AQ
Skye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, Nimacimab	Dec. 11	AQ
Skye Bioscience Responds to OTC Markets Promotional Policy	Dec. 08	NE
Ocular Hypertension Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 \| Nicox, Qlaris Bio, TheratOcular Biotek Co., Ltd., Ocular Therapeutix, Whitecap Biosciences, and others.	Dec. 06	AQ
Skye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of Africa	Dec. 05	NE
Skye Bioscience Treats First Patient in Glaucoma Phase 2 Study of SBI-100 Ophthalmic Emulsion	Nov. 28	AQ
Skye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation Summit	Nov. 21	NE
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma	23-10-25	NE
CORRECTION, Skye Bioscience to Host Virtual Investor Day on October 25, 2023, 'CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System'	23-10-23	AQ
Skye Bioscience to Host Virtual Investor Day on October 25, 2023: "CB1 Axis: Unlocking the Pharmaceutical Potential of the Endocannabinoid System"	23-10-20	NE
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial	23-09-27	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Skye Bioscience, Inc.

Equities

EMBI

US83086J2006

Press Releases

Filters